AKERO THERAPEUTICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.62 USD | +4.96% |
|
-6.29% | -11.26% |
Presenter SpeechEric Joseph (Analysts)All right. Good morning, and thanks again for joining us...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Akero Therapeutics, Inc. is a clinical-stage company. The Company is developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH), a disease without any approved therapies. Efruxifermin (EFX), is its lead product candidate for MASH, which is being evaluated in the ongoing phase IIb SYMMETRY, phase III SYNCHRONY Histology, and phase III SYNCHRONY real-world studies. The phase III SYNCHRONY program builds on the results of two phase IIb clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with cirrhosis due to MASH. EFX is an analog of fibroblast growth factor 21 (FGF21), which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. EFX is designed to offer convenient once-weekly dosing.
Calendar
2024-05-14
- BofA Securities Health Care Conference
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
19.65
USD
Average target price
47
USD
Spread / Average Target
+139.19%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -11.26% | 1.36B | |
| +4.89% | 109B | |
| +10.86% | 105B | |
| -0.38% | 22.25B | |
| -11.69% | 22.09B | |
| -7.66% | 18.68B | |
| -36.52% | 17.58B | |
| -9.57% | 16.85B | |
| +4.01% | 13.76B | |
| +35.58% | 12.46B |
- Stock Market
- Equities
- AKRO Stock
- News Akero Therapeutics, Inc.
- Transcript : Akero Therapeutics, Inc. Presents at 39th Annual JPMorgan Virtual Healthcare Conference, Jan-12-2021 07
